Omeprazole/antacids swallowable tablet - Salix Pharmaceuticals

Drug Profile

Omeprazole/antacids swallowable tablet - Salix Pharmaceuticals

Alternative Names: Magnesium hydroxide/sodium bicarbonate/omeprazole; Omeprazole/antacids; Sodium bicarbonate/omeprazole/magnesium hydroxide; Zegerid swallowable tablets

Latest Information Update: 04 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santarus
  • Developer Salix Pharmaceuticals
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Gastric antisecretories; Small molecules
  • Mechanism of Action Antacids; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Gastrointestinal disorders; Heartburn

Most Recent Events

  • 02 Jan 2014 Santarus has been acquired and merged into Salix Pharmaceuticals
  • 31 Oct 2011 Norgine completes a phase III trial in Heartburn in Poland (NCT01493089)
  • 08 Sep 2011 Norgine completes a phase III trial in Heartburn in Bulgaria, Czech Republic, UK and Hungary (EudraCT 2010-022082-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top